Efficacy of 2LPAPI<sup>®</sup>, a Micro-Immunotherapy Drug, in Patients with High-Risk Papillomavirus Genital Infection

Abstract

Human papillomaviruses (HPVs) are well known for being linked to the development of cervical cancers, most of them being caused by the high-risk (HR) oncogenic genotypes, mainly 16 and 18. The efficacy of 2LPAPI ® (Labo'Life), a micro-immunotherapy homeopathic drug, has been evaluated in HR-HPV infected women (n = 18), in a private gynecology practice, by comparing them to an untreated control group (n = 18). Patients were 20 to 45 years old and had cytology with Atypical Squamous Cells of Undetermined Significance (ASCUS) or Low grade Superficial Intra Lesions/ Cervical Intraepithelial Neoplasia Grade I (LSIL/CINI). Patients freely chose to be treated with the drug or not. Those deciding not to take the drug remained untreated and were followed as a control group. The drug was taken at the regimen of one capsule per day during 6 months. HR-HPV and cytology were evaluated at 6 and 12 months. After 12 months, HR-HPV was cleared in 78% of the patients taking the drug versus 44% in those not taking it (p = 0.086). In patients over 25 years, HR-HPV clearance in the treated group was significantly higher (81.3%) than in the control group (20%) (p = 0.004). The difference in the regression of the lesion grades almost reached statistical significance (p = 0.053). This follow-up confirms that the micro-immunotherapy drug 2LPAPI ® is a safe and effective therapeutic approach to treat HR-HPV cervical lesions in women over 25 years.

Pro-Inflammatory Cytokines at Ultra-Low Dose Exert Anti-Inflammatory Effect In Vitro: A Possible Mode of Action Involving Sub-Micron Particles?

“…The composition of MI medicines is expressed as number of Centesimal Hahnemannian dilutions (CH), as in traditional homeopathic medicines. 6 - 13 LD range from 3 to 7 CH and aim at stimulating the expression of specific proteins and molecular pathways, for example to reduce oxidative stress, 7 while ULD aim at regulating (from 8 to 10 CH) and/or inhibiting (higher than 10 CH) the expression of certain key proteins involved in IMIDs, to reestablish the homeostasis. TNF-α and IL-1β are therapeutic targets used in MI at inhibiting ULD to counteract their overexpression.…”

“…Furthermore, clinical data also described the potential benefit of the therapy in several acute 11 and chronic diseases. 12 , 13 Nevertheless, further investigations are needed to comprehend, at the molecular level, the mechanism of MI. The hypothesized mode of action of LD and ULD, on which MI medicines are based, mainly involves 2 conserved core biological features: i) all organisms, cells and tissues, particularly the immune system, can respond to a multitude of stimuli, in a wide range of concentrations, according to a non-linear dose−response curve, also called biphasic or hormetic response 14 ; ii) all organisms, tissues and cells have the capacity to adapt to environmental signals and stressors with a high plasticity and with the aim to reestablish the homeostasis.…”

Potential Role of the Micro-Immunotherapy Medicine 2LALERG in the Treatment of Pollen-Induced Allergic Inflammation

“…SNAs consist of single strands of DNA molecules, ranging from 16 to 34 bases, designed to target specifically 1 or more genes (European Patent: EP0670164B1). 13 -15…”

2LARTH^®, a micro-immunotherapy medicine, exerts anti-inflammatory effects in vitro and reduces TNF-α and IL-1β secretion

“…MI acts to potentiate the body’s defenses in acute and chronic diseases. 1 , 2 MI medicines consist of lactose-saccharose globules for oromucosal administration, impregnated with ethanolic preparations of immune mediators and nucleic acids at ultra-low doses (ULD). ULD of active substances are obtained through the “Sequential Kinetic Process”, consisting of a 1/100 dilution process followed by verti cal shaking, reproduced a defined number of times.…”